Business
AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
VANCOUVER, British Columbia, May 11, 2026--AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
About this update from Abcellera Biologics Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":339,"url":"https://media.zenfs.com/en/business-wire.com/9a897265d1780aae5eaeec20e838b6ca"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/p7WerlNo4WaCov8c7okAZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY3OA--/https://media.zenfs.com/en/business-wire.com/9a897265d1780aae5eaeec20e838b6ca","width":480,"height":339},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/2B8xM9p5WI_uuZcD3Yo8GA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQ1Mg--/https://media.zenfs.com/en/business-wire.com/9a897265d1780aae5eaeec20e838b6ca","width":480,"height":339}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"ABCL635 demonstrated a favorable tolerability profile, with no observed liver toxicity, and achieved potent and sustained reductions in biomarkers of target engagement.","length":168,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Ended Q1 2026 with total available liquidity of approximately $655 million.","length":75,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":243,"olType":false},{"type":"text","content":"VANCOUVER, British Columbia, May 11, 2026--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2026 and positive interim results from the Phase 1 portion of its ongoing Phase 1/2 clinical trial of ABCL635. ABCL635 is a potential first-in-class antibody targeting the neurokinin 3 receptor (NK3R) for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.","length":541,"tagName":"p"},{"type":"text","content":""We are excited to share interim Phase 1 data that show ABCL635 achieved robust NK3R target engagement at doses that were well-tolerated in healthy volunteers and a pharmacokinetic profile that may support a once monthly dosing regimen. We look forward to the efficacy readout from the Phase 2 data in Q3, which we believe will be highly de-risking for the program," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "Through 2026 we are focused on delivering data readouts for our clinical programs, advancing ABCL688 and ABCL386 into IND-e...